Previous 10 | Next 10 |
PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced th...
2023-06-16 10:08:10 ET Gainers: Oncorus ( ONCR ) +264% . Microbot Medical ( MBOT ) +24% . NeuBase Therapeutics ( NBSE ) +19% . Community Health Systems ( CYH ) +8% . Homology Medicines ( FIXX ) +4% . Losers: Panbela Therap...
2023-06-14 09:03:15 ET NeuBase Therapeutics said Wednesday that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 to regain compliance with Nasdaq's listing rule. The stock split will be effective as of 5:00 p.m. ET on June 14,...
PITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today anno...
PITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today annou...
Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machinery Data show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution ...
PITTSBURGH, May 16, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced...
2023-05-11 17:22:14 ET NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.12 misses by $0.02 . For the quarter ended March 31, 2023, total operating expenses were approximately $4.2 million, consisting of approximately $2.9 million in general and a...
Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 ...
PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepte...
News, Short Squeeze, Breakout and More Instantly...
NeuBase Therapeutics Inc. Company Name:
NBSE Stock Symbol:
NYSE Market:
NeuBase Therapeutics Inc. Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
Macquarie Group Ltd ADR (MQBKY) is expected to report for Q4 2024 Hormel Foods Corporation (HRL) is expected to report $0.35 for Q2 2024 Howden Joinery Group Plc ADR (HWDJY) is expected to report for Q1 2024 Eiger BioPharmaceuticals Inc. (EIGRQ) is expected to report for Q1 2024 M...